An Effect of Letrozole on Gastric Cancer?

Abstract

Letrozole is a drug used in the treatment of postmenopausal women with breast and ovarian tumours. There is no evidence in the literature indicating its use in treating gastric cancer. We present a 68 year old lady admitted from the emergency department with weight loss, malaise and anaemia. Investigations confirmed the presence of two different primary tumours in the left breast and the stomach. Following that this patient with oestrogen receptor positive breast cancer and oestrogen receptor negative gastric cancer was treated with letrozole for her breast cancer followed by a gastric resection. Independent histology by two pathologists pre-operatively diagnosed gastric adenocarcinoma. Post-operatively, independent analysis of the resected stomach, omentum and lymph nodes revealed no evidence of gastric cancer. Therefore we conclude that there is a possibility of letrozole having an effect on gastric cancer. Further studies are needed.

Changes of Tyrosine Phosphorylation in Liver and Kidney of Polycystic Ovarian Rats Induced by Letrozole

“…Letrozole (Letro) or Femara is a non-steroidal aromatase inhibitor clinically used to reduce estrogen level via steroidal synthesis inhibition for breast cancer treatment (He & Ma, 2016) and to delay cancer cell metastasis (Wang et al, 2016). The Letro was also used for gastric cancer treatment (El Hadi, 2011). As it has property like aromatase inhibitor, Letro commonly used to induce polycystic ovary syndrome (PCOS) in the animal model in study of its mechanism and prevention for PCOS infertile patients.…”

Long-term response on letrozole for gastric cancer

“…Clinically, there is only 1 report demonstrating the clinical effect of hormone therapy on GC [6] . They reported a case with ER-positive breast cancer treated with letrozole.…”

“…[10] Clinically, there is only 1 report demonstrating the clinical effect of hormone therapy on GC. [6] They reported a case with ER-positive breast cancer treated with letrozole. The patient also suffered from independent primary GC with no ER expression and decided to initially start with letrozole treatment to regulate the breast cancer.…”

“…Recently, many investigators have explored the potential of applying hormone therapy on GC, particularly targeting estrogen and estrogen receptor (ER). [6][7][8][9] Hormone therapy targeting Editor: Maya Saranathan.…”

“…Recently, many investigators have explored the potential of applying hormone therapy on GC, particularly targeting estrogen and estrogen receptor (ER) [6–9] . Hormone therapy targeting estrogen consists of an aromatase inhibitor, an ER inhibitor (tamoxifen), and a selective ER degrader (fulvestrant) [10] .…”